SEC Form 4 · accession 0000899243-17-010077
AGENUS INC · AGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Garo H Armen
Officer — Chairman & CEO · Director
Period of report
Apr 10, 2017
Accepted (ET)
Apr 12, 2017 · 5:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001098972
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 10, 2017 | P | 70,544 | $3.3662 | A | 1,389,021 | D | |
| Common StockF2 | Apr 12, 2017 | P | 29,456 | $3.2949 | A | 1,418,477 | D | |
| Common StockF3 | holding | — | — | — | 4,046 | I | By Antigenics Holdings |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.29 to $3.43. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares purchased at each price.
- F2This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.255 to $3.33. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares purchased at each price.
- F3Dr. Armen is Chairman of the Board of Managers and a member of Antigenics Holdings LLC ("Holdings") which as of the date of this report owns 4,046 shares of Agenus Inc. common stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Holdings and disclaims beneficial ownership to the extent of his pecuniary interest therein.